Explore the words cloud of the RESIST3D project. It provides you a very rough idea of what is the project "RESIST3D" about.
The following table provides information about the project.
|Coordinator Country||Denmark [DK]|
|Total cost||207˙312 €|
|EC max contribution||207˙312 € (100%)|
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
|Duration (year-month-day)||from 2020-09-01 to 2022-08-31|
Take a look of project's partnership.
|1||KOBENHAVNS UNIVERSITET||DK (KOBENHAVN)||coordinator||207˙312.00|
Ovarian cancer is the fifth most deadly cancer type among women in Europe. Despite the fact that standard chemotherapy is usually effective in eliminating bulk tumour mass, thereby inducing remission, most patients diagnosed with advanced ovarian cancer die from the disease, as relapsed lesions emerge from small subpopulations of surviving drug-resistant cells. Precision medicine aims to improve cancer care through tailoring individualized therapies based on genomic or functional profiling of human cancers. However, as these approaches are usually performed on bulk tumour cells, the small pre-existing drug-resistant cell subpopulations remain untargeted. In the RESIST3D project, I will utilize ovarian cancer organoids – a patient-derived, three-dimensional cell cultures – to search for new strategies to eradicate drug-resistant cancer cells. I will use two organoid models developed for the same patient – one model derived from tumour material taken before chemotherapeutic treatment and one from a post-treatment sample, typically enriched in drug-resistant cells. I will further enrich the organoids in quiescent, drug-resistant cells by maintaining them in physiologic-like culture medium. I will then apply the models for drug-response profiling in order to identify agents that eradicate pre-existing drug-resistant cells, which could be combined with standard chemotherapy. Finally, I will assess whether the selected combinations prevent relapses in patient-derived xenograft mouse models. RESIST3D sets a new direction in precision cancer medicine, as it focuses on targeting small pre-existing subpopulations of drug-resistant cells rather than bulk tumour mass. Through combining organoid model, paired samples for each patient and physiologic culture conditions, I expect to identify new ways to target drug-resistant ovarian cancer cells. Moreover, RESIST3D will provide me with new research expertise and a scientific network that will enhance my research career.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RESIST3D" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "RESIST3D" are provided by the European Opendata Portal: CORDIS opendata.
Disfluencies and Eye MOvements during Speech: what can they reveal about language production?Read More
Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and IconographyRead More
How other minds are represented in the human brain: Neural computations underlying Theory of MindRead More